Literature DB >> 23152491

Hemodynamic determinants of dyspnea improvement in acute decompensated heart failure.

Amir Solomonica1, Andrew J Burger, Doron Aronson.   

Abstract

BACKGROUND: Dyspnea relief constitutes a major treatment goal and a key measure of treatment efficacy in decompensated heart failure. However, there are no data with regard to the relationship between hemodynamic measurements during treatment and dyspnea improvement. METHODS AND
RESULTS: We studied 233 patients assigned to right heart catheterization in the Vasodilation in the Management of Acute Congestive Heart Failure trial. Dyspnea (assessed using a 7-point Likert scale) and hemodynamic parameters were measured simultaneously at 15 and 30 minutes and 1, 2, 3, 6, and 24 hours. Dyspnea relief was defined as moderate or marked improvement. There was a time-dependent association between the reductions in pulmonary capillary wedge pressure (PCWP; 25.4, 24.6, 24.0, 23.5, 23.4, 21.5, and 19.9 mm Hg) and the percentage of patients achieving dyspnea relief (17.7%, 24.6%, 32.2%, 36.2%, 37.8%, 47.4%, and 66.1%, in the respective time points). Multivariable logistic generalized estimating equations modeling demonstrated that reductions of both PCWP and mean pulmonary artery pressure were independently associated with dyspnea relief. Compared with the highest PCWP quartile, the adjusted odds ratios for dyspnea relief were 0.92 (95% confidence interval [CI], 0.67-1.29), 1.07 (95% CI, 0.75-1.55), and 1.80 (95% CI, 1.22-2.65) in the third, second, and first PCWP quartiles, respectively (P(trend)=0.003). Compared with the highest mean pulmonary artery pressure quartile, the adjusted odds ratios for dyspnea relief were 2.0 (95% CI, 1.41-2.82), 2.23 (95% CI, 1.52-3.27), and 2.98 (95% CI, 1.91-4.66) in the third, second, and first mean pulmonary artery pressure quartiles, respectively (P(trend)<0.0001).
CONCLUSIONS: A clinically significant improvement in dyspnea is associated with a reduction in both PCWP and mean pulmonary artery pressure.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23152491     DOI: 10.1161/CIRCHEARTFAILURE.112.970335

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  10 in total

1.  A novel technique to predict pulmonary capillary wedge pressure utilizing central venous pressure and tissue Doppler tricuspid/mitral annular velocities.

Authors:  Kazunori Uemura; Masashi Inagaki; Can Zheng; Meihua Li; Toru Kawada; Masaru Sugimachi
Journal:  Heart Vessels       Date:  2014-05-31       Impact factor: 2.037

2.  Hemodynamic Correlates and Diagnostic Role of Cardiopulmonary Exercise Testing in Heart Failure With Preserved Ejection Fraction.

Authors:  Yogesh N V Reddy; Thomas P Olson; Masaru Obokata; Vojtech Melenovsky; Barry A Borlaug
Journal:  JACC Heart Fail       Date:  2018-05-23       Impact factor: 12.035

3.  A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure.

Authors:  Piotr Ponikowski; Veselin Mitrovic; Mikhail Ruda; Alberto Fernandez; Adriaan A Voors; Alexander Vishnevsky; Gad Cotter; Olga Milo; Ute Laessing; Yiming Zhang; Marion Dahlke; Robert Zymlinski; Marco Metra
Journal:  Eur Heart J       Date:  2013-11-18       Impact factor: 29.983

4.  Oxidative stress markers and C-reactive protein are related to severity of heart failure in patients with dilated cardiomyopathy.

Authors:  Celina Wojciechowska; Ewa Romuk; Andrzej Tomasik; Bronisława Skrzep-Poloczek; Ewa Nowalany-Kozielska; Ewa Birkner; Wojciech Jacheć
Journal:  Mediators Inflamm       Date:  2014-10-23       Impact factor: 4.711

5.  One-Year Outcomes After Transcatheter Insertion of an Interatrial Shunt Device for the Management of Heart Failure With Preserved Ejection Fraction.

Authors:  David M Kaye; Gerd Hasenfuß; Petr Neuzil; Martijn C Post; Robert Doughty; Jean-Noël Trochu; Adam Kolodziej; Ralf Westenfeld; Martin Penicka; Mark Rosenberg; Antony Walton; David Muller; Darren Walters; Jorg Hausleiter; Philip Raake; Mark C Petrie; Martin Bergmann; Guillaume Jondeau; Ted Feldman; Dirk J van Veldhuisen; Piotr Ponikowski; Frank E Silvestry; Dan Burkhoff; Christopher Hayward
Journal:  Circ Heart Fail       Date:  2016-12       Impact factor: 8.790

6.  Sex differences in early dyspnea relief between men and women hospitalized for acute heart failure: insights from the RELAX-AHF study.

Authors:  Sven Meyer; John R Teerlink; Marco Metra; Piotr Ponikowski; Gad Cotter; Beth A Davison; G Michael Felker; Gerasimos Filippatos; Barry H Greenberg; Tsushung A Hua; Thomas Severin; Min Qian; Adriaan A Voors
Journal:  Clin Res Cardiol       Date:  2016-11-12       Impact factor: 5.460

7.  Patterns of dyspnoea onset in patients with acute heart failure: clinical and prognostic implications.

Authors:  Justyna Maria Sokolska; Mateusz Sokolski; Robert Zymliński; Jan Biegus; Paweł Siwołowski; Sylwia Nawrocka-Millward; Ewa Anita Jankowska; John Todd; Waldemar Banasiak; Piotr Ponikowski
Journal:  ESC Heart Fail       Date:  2018-11-13

8.  The Utility of Predicting Hospitalizations Among Patients With Heart Failure Using mHealth: Observational Study.

Authors:  Susie Cartledge; Ralph Maddison; Sara Vogrin; Roman Falls; Odgerel Tumur; Ingrid Hopper; Christopher Neil
Journal:  JMIR Mhealth Uhealth       Date:  2020-12-22       Impact factor: 4.773

9.  Symptom phenotypes in pulmonary arterial hypertension: The PAH "symptome".

Authors:  Lea Ann Matura; Jamison D Fargo; Kathleen Boyle; Jason S Fritz; Kerri A Smith; Jeremy A Mazurek; Diane Pinder; Christine L Archer-Chicko; Harold I Palevsky; Allan I Pack; Marilyn S Sommers; Steven M Kawut
Journal:  Pulm Circ       Date:  2022-07-01       Impact factor: 2.886

10.  Body fluid status assessment by bio-impedance analysis in patients presenting to the emergency department with dyspnea.

Authors:  Chan Soon Park; Sang-Eun Lee; Hyun-Jai Cho; Yong-Jin Kim; Hyun-Jae Kang; Byung-Hee Oh; Hae-Young Lee
Journal:  Korean J Intern Med       Date:  2017-12-18       Impact factor: 2.884

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.